Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Physiomics ( (GB:PYC) ) has shared an announcement.
Physiomics plc announced a new contract with Numab Therapeutics AG to support the pre-clinical development of a multi-specific antibody for autoimmune diseases. This collaboration will involve developing a mechanistic PK/PD model to enhance understanding of the drug’s behavior and inform dosing decisions for preclinical and clinical studies. The project highlights the significance of Model Informed Drug Development in the drug development lifecycle, reinforcing Physiomics’ role in advancing therapeutic antibody pipelines for both oncology and autoimmune indications.
Spark’s Take on GB:PYC Stock
According to Spark, TipRanks’ AI Analyst, GB:PYC is a Underperform.
Physiomics’ stock score is primarily impacted by significant financial instability, including declining revenues and negative profit margins. Technical indicators reinforce a bearish outlook. While recent corporate events suggest potential growth pathways, current valuation issues and financial challenges remain significant obstacles.
To see Spark’s full report on GB:PYC stock, click here.
More about Physiomics
Physiomics plc is a leading company in mathematical modelling, data science, and biostatistics, focusing on the development of new therapeutics and personalized medicine solutions. The company leverages expertise in Modelling & Simulation, Biostatistics, Data Science, and Bioinformatics to aid biotech and pharma companies in optimizing their drug development processes. Their services help in de-risking decision-making and optimizing research design across discovery, pre-clinical, and clinical studies. Physiomics has contributed to over 100 commercial projects and collaborated with notable clients such as Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics, and CRUK.
Average Trading Volume: 3,607,157
Technical Sentiment Signal: Sell
Current Market Cap: £879.3K
See more insights into PYC stock on TipRanks’ Stock Analysis page.